Hospital News

Nesher Pharma gets FDA nod for ADHD drugs

Views: 987

A subsidiary of drug firm of Zydus, Nesher Pharmaceuticals, has received FDA approval to market Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets —used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy —in strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg.

Zydus said the drug will be produced at the Nesher Pharmaceuticals’ manufacturing facility located in St. Louis, MO, USA.

The sales of Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets are estimated at the US $416.5 million.

With the FDA nod of ADHD tablet, the group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.


Most Popular





Get Heard Portal


eHealth Event Report




About Us

eHEALTH, as an online and print platform, elegantly guides the healthcare stakeholders through the trajectory of healthcare that witnesses fascinating changes on a daily basis due to increased technological intervention and other structural changes to create a ‘community of practice’ of healthcare stakeholders.


Contact Us

Elets Technomedia Pvt. Ltd.
Stellar IT Park, Office No. 7A/7B, 5th Floor, Tower -2 Annexe Building, C-25, Sector 62 Noida, Uttar Pradesh - 201309, India

Copyright © 2018 Elets | All rights reserved

To Top